%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates
2018/12/03
藥明康德入選上證50、上證180、滬深300、中證100指數樣本股
今日，上海證券交易所、中證指數公司等發佈公告，經指數專家委員會審議，將對上證50、上證180、滬深300、中證100等A股指數樣本股進行調整。藥明康德（股票代碼：603259.SH）憑藉上市以來在資本市場上的穩健表現，將被調入上述四項指數的樣本股。相關調整將從2018年12月17日起實行
閲讀更多2018/11/28
藥明康德榮膺弗若斯特沙利文“2018全球一體化藥物研發服務戰略創新及領導力獎”
昨日，國際權威諮詢機構弗若斯特沙利文（Frost & Sullivan）公佈了2018年度“最佳實踐獎”（Frost & Sullivan Best Practices Awards）評選結果，藥明康德憑藉其全方位一體化的開放式賦能平台，榮獲“2018全球一體化藥物研發服務戰略創新及領導力獎”，這是藥明康德連續第二年獲此殊榮
閲讀更多2018/11/15
藥明康德榮獲百華協會“2018年度企業獎”
上海，2018年11月15日——昨日，在第五屆中國醫療健康峰會上，藥明康德榮獲百華協會（The BayHelix Group）頒發的2018中國醫療獎之“年度企業獎”（Company of the Year），該獎項旨在表彰在中國醫療行業取得傑出成就，並對大健康生態圈做出突出貢獻的企業。藥明康德執行副總裁、首席商務官楊青博士受邀出席並接受頒獎。
閲讀更多2018/09/25
藥明康德宣佈在江蘇啟東設立研發中心
江蘇啟東，2018年9月25日 --藥明康德（股票代碼：603259.SH）今日與啟東市人民政府正式簽署戰略合作協議，宣佈在啟東設立研發中心。藥明康德落戶啟東將進一步助力啟東生命健康科技城的建設與發展，有效吸引更多創新企業和人才集聚啟東。未來，啟東將成為藥明康德上海研發副中心基地，從而更好地為本地乃至全球客戶賦能，造福廣大病患。
閲讀更多2018/09/06
藥明康德祝賀合作夥伴和記黃埔醫藥抗癌新藥呋喹替尼在中國獲批上市
中國上海，2018年9月6日-藥明康德（股票代碼：603259.SH）熱烈祝賀合作夥伴和記黃埔醫藥（上海）有限公司（下稱和記黃埔醫藥）用於治療轉移性結直腸癌的新藥呋喹替尼膠囊（愛優特®）獲國家藥品監督管理局批准上市。呋喹替尼膠囊為境內外均未上市的創新藥，通過優先審評審批程序獲准上市，給中國廣大結腸癌患者帶來了福音。這是中國藥品上市許可持有人制度（MAH）試點開展以來，藥明康德子公司合全藥業所支持的第二款成功上市的1類創新藥。
閲讀更多